Market Cap 132.09M
Revenue (ttm) 114.20M
Net Income (ttm) 120,000.00
EPS (ttm) N/A
PE Ratio 7.57
Forward PE 7.82
Profit Margin 0.11%
Debt to Equity Ratio -0.16
Volume 321,600
Avg Vol 586,688
Day's Range N/A - N/A
Shares Out 38.40M
Stochastic %K 11%
Beta 1.57
Analysts Sell
Price Target $12.33

Company Profile

Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 674 4400
Fax: 781 674 4200
Address:
3 Forbes Road, Lexington, United States
weichsel1
weichsel1 Mar. 27 at 10:42 PM
$AGEN just drifting lower daily
1 · Reply
Biotechguy21
Biotechguy21 Mar. 27 at 10:05 PM
$AGEN looking like a big run is coming 😂😂😂🤡🤡🤡💰💰💰
0 · Reply
Overcrumb
Overcrumb Mar. 27 at 7:02 PM
$AGEN is it just me, or does anyone else think it’s strange Agenus’s stock price to decline on the days that Mink’s SP goes up?
1 · Reply
tyrus6
tyrus6 Mar. 27 at 5:46 PM
$AGEN $EXEL is an even better example. From 2000 to 2016 its share price dropped from $ 50 to $ 1.25 in 2016. EXEL hit $49 last June. Breakthrough came with cancer drug Cabozantinib (Cabometyx) Exelixis is especially relevant because: ✔ It did a reverse split during its darkest period ✔ Looked like a “typical failing biotech” beforehand ✔ Then one key asset delivered real clinical + commercial success ✔ Transitioned into a self-sustaining revenue company So basically any newbies buying AGEN here, like me, are hoping we are all north of the stock's lowpoint. Past struggles do NOT preclude multibillion dollar market cap sucess. As always, investing is about good timing.
0 · Reply
Doom_Gloom_AR
Doom_Gloom_AR Mar. 27 at 5:43 PM
$AGEN maybe mink will get some ibrx $. Would be a good move, potentially fund a p3 neoadjuvant mas crc.
1 · Reply
tyrus6
tyrus6 Mar. 27 at 5:25 PM
$AGEN $PCYC From early 2000 to 2008, shareholders in Pharmacyclics (PCYC) saw the stock decline from $ 80 a share to 55 cents per share. Stuff happens in biotech. Hoped-for success gets delayed. Timing is everything. Trashing the ceo constantly probably got some PCYC investors through their day for 8 years, too.
0 · Reply
Biotechguy21
Biotechguy21 Mar. 27 at 5:00 PM
$AGEN #1 ceo out there. thank you Garo!!!!!
0 · Reply
Biotechguy21
Biotechguy21 Mar. 27 at 4:59 PM
$AGEN truth. this ceo has been the reason this is a pos stock. 30 years of Clownshow moves and atm activity. 96% losses. Congrats to Garo. Thank you sir 🤡🤡🤡😂😂💰💰💩💩🙏🙏
0 · Reply
joechuck71
joechuck71 Mar. 27 at 4:29 PM
$AGEN Director, Safety Science (MD) Remote Full time 1162 Global Events & Program Operations Senior Associate Lexington, MA Full time 1160 Regional Medical Leader(MSL) (Oncology/Immuno-Oncology/GI) France Full time 1161 Senior Manager, Pharmacovigilance Operations Remote Full time 1144
0 · Reply
pedmac2000
pedmac2000 Mar. 27 at 4:23 PM
$AGEN mink up 20 Pct ? Maybe partnership ?
1 · Reply
Latest News on AGEN
Agenus to Host First 2026 Stakeholder Webcast

Jan 20, 2026, 6:24 PM EST - 2 months ago

Agenus to Host First 2026 Stakeholder Webcast


Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript

Dec 4, 2025, 1:43 AM EST - 4 months ago

Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript


Agenus Announces Virtual Annual Shareholders Meeting

Jun 10, 2025, 1:30 PM EDT - 10 months ago

Agenus Announces Virtual Annual Shareholders Meeting


Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang

Jun 4, 2025, 2:38 PM EDT - 10 months ago

Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang


Agenus: Big On BOT/BAL As Cash Burn And Catalysts Collide

May 23, 2025, 3:09 PM EDT - 11 months ago

Agenus: Big On BOT/BAL As Cash Burn And Catalysts Collide


Agenus Inc. (AGEN) Q1 2025 Earnings Call Transcript

May 12, 2025, 2:46 PM EDT - 11 months ago

Agenus Inc. (AGEN) Q1 2025 Earnings Call Transcript


Agenus Reports Q1 2025 Financial Results and Key Business Updates

May 12, 2025, 7:30 AM EDT - 11 months ago

Agenus Reports Q1 2025 Financial Results and Key Business Updates


Agenus Inc. (AGEN) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 10:39 AM EDT - 1 year ago

Agenus Inc. (AGEN) Q4 2024 Earnings Call Transcript


weichsel1
weichsel1 Mar. 27 at 10:42 PM
$AGEN just drifting lower daily
1 · Reply
Biotechguy21
Biotechguy21 Mar. 27 at 10:05 PM
$AGEN looking like a big run is coming 😂😂😂🤡🤡🤡💰💰💰
0 · Reply
Overcrumb
Overcrumb Mar. 27 at 7:02 PM
$AGEN is it just me, or does anyone else think it’s strange Agenus’s stock price to decline on the days that Mink’s SP goes up?
1 · Reply
tyrus6
tyrus6 Mar. 27 at 5:46 PM
$AGEN $EXEL is an even better example. From 2000 to 2016 its share price dropped from $ 50 to $ 1.25 in 2016. EXEL hit $49 last June. Breakthrough came with cancer drug Cabozantinib (Cabometyx) Exelixis is especially relevant because: ✔ It did a reverse split during its darkest period ✔ Looked like a “typical failing biotech” beforehand ✔ Then one key asset delivered real clinical + commercial success ✔ Transitioned into a self-sustaining revenue company So basically any newbies buying AGEN here, like me, are hoping we are all north of the stock's lowpoint. Past struggles do NOT preclude multibillion dollar market cap sucess. As always, investing is about good timing.
0 · Reply
Doom_Gloom_AR
Doom_Gloom_AR Mar. 27 at 5:43 PM
$AGEN maybe mink will get some ibrx $. Would be a good move, potentially fund a p3 neoadjuvant mas crc.
1 · Reply
tyrus6
tyrus6 Mar. 27 at 5:25 PM
$AGEN $PCYC From early 2000 to 2008, shareholders in Pharmacyclics (PCYC) saw the stock decline from $ 80 a share to 55 cents per share. Stuff happens in biotech. Hoped-for success gets delayed. Timing is everything. Trashing the ceo constantly probably got some PCYC investors through their day for 8 years, too.
0 · Reply
Biotechguy21
Biotechguy21 Mar. 27 at 5:00 PM
$AGEN #1 ceo out there. thank you Garo!!!!!
0 · Reply
Biotechguy21
Biotechguy21 Mar. 27 at 4:59 PM
$AGEN truth. this ceo has been the reason this is a pos stock. 30 years of Clownshow moves and atm activity. 96% losses. Congrats to Garo. Thank you sir 🤡🤡🤡😂😂💰💰💩💩🙏🙏
0 · Reply
joechuck71
joechuck71 Mar. 27 at 4:29 PM
$AGEN Director, Safety Science (MD) Remote Full time 1162 Global Events & Program Operations Senior Associate Lexington, MA Full time 1160 Regional Medical Leader(MSL) (Oncology/Immuno-Oncology/GI) France Full time 1161 Senior Manager, Pharmacovigilance Operations Remote Full time 1144
0 · Reply
pedmac2000
pedmac2000 Mar. 27 at 4:23 PM
$AGEN mink up 20 Pct ? Maybe partnership ?
1 · Reply
joechuck71
joechuck71 Mar. 27 at 4:20 PM
0 · Reply
JohnG8
JohnG8 Mar. 27 at 4:11 PM
$AGEN and for those of you who weren’t around in the early days of bot/bal, Garo was saying all the time that a deal was just around the corner. It was a theme hammered home. And guess what, there was no deal. If there would’ve been a deal with BP, we could’ve explored all the indications, the P2 would’ve been designed correctly, and we would’ve likely gotten AA, we would be in partnership with a BP who had influence with FDA, and this stock would be 100 instead of 3. You haven’t been around long enough to know Garo the way I know Garo. You are a fool to believe him. 
4 · Reply
2_logs_higher
2_logs_higher Mar. 27 at 3:58 PM
$AGEN & $INKT
1 · Reply
joechuck71
joechuck71 Mar. 27 at 3:31 PM
$AGEN remember we own a few shares if mink explodes so will Agenus bank book can we do this all without a partner most would say no i will say maybe yes. March 27 (Reuters) - Mink Therapeutics Inc(INKT): * MINK THERAPEUTICS INC(INKT) - IN DISCUSSIONS FOR POTENTIAL COMBINATION TRIALS AND STRATEGIC MINORITY INVESTMENTS - SEC FILING * MINK THERAPEUTICS(INKT): IN DISCUSSIONS WITH MULTIPLE PARTIES REGARDING POTENTIAL COMBINATION TRIALS INVOLVING AGENT-797 * MINK THERAPEUTICS INC(INKT) - HAS NOT PUBLICLY DISCLOSED ANY BINDING ARRANGEMENTS FOR COMBINATION TRIALS OR STRATEGIC INVESTMENTS - SEC FILING Source text: Further company coverage
0 · Reply
JohnG8
JohnG8 Mar. 27 at 3:08 PM
$AGEN I don’t want to rain on the wonderful Garo narrative infecting these pages, but just to point out that with 2 groundbreaking drugs he has managed to sink this share price from a high of 121 to $3.40. To successfully go it alone, which is what he has chosen to do, he needed to be brilliant. He needed to be Elon Musk brilliant. Unfortunately, he is not anywhere close to competent. In addition, don’t think for a minute that he has the benefit of shareholders in mind at any time in his thinking process. He is not partnering now because he would be playing in the big leagues with the big boys, and he can’t hack that. Or rather, his ego can’t hack that. Or, it is very possible that the OS numbers are actually not very good, which is why they are being hidden from us, in which case he is just a run-of-the-mill scammer.….. time will tell, and shareholders will be the last to know.
1 · Reply
Biotechguy21
Biotechguy21 Mar. 27 at 2:17 PM
$AGEN the losers are getting desperate bc they are down 96% on this pos stock. Stay tuned $INKT $PTIX
0 · Reply
Biotechguy21
Biotechguy21 Mar. 27 at 2:16 PM
$AGEN $GOOGL take a look at a pos company run by a bunch of atm fools 🤡🤡🤡🤡
0 · Reply
Biotechguy21
Biotechguy21 Mar. 27 at 2:15 PM
$AGEN $BTC.X you are so wrong. Typical $AGEN $INKT 🤡🤡🤡🤡
0 · Reply
BakerBrother
BakerBrother Mar. 27 at 2:15 PM
$BTC.X crypto is valued at $2,5 trillion but it’s worth $0. $AGEN is curing cancer. Might be worth a look.
1 · Reply
tyrus6
tyrus6 Mar. 27 at 1:27 PM
0 · Reply
BakerBrother
BakerBrother Mar. 27 at 12:17 PM
$GOOGL $AGEN is curing cancer take a look!
0 · Reply
Biotechguy21
Biotechguy21 Mar. 27 at 11:59 AM
$AGEN did you mean the scam call?
0 · Reply